
    
      Patients with RMS receiving Ocrelizumab or Ofatumumab will be recruited to measure the time
      spend for Healthcare Providers (HCP) (neurologist, nurse and hospital pharmacist) on
      preparing, administering the medication and following up with the patient.
    
  